Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Corvus Pharmaceuticals Q3 net loss more than doubles to $20.34 million

By Public Technologies
  • Corvus Pharmaceuticals’ third-quarter 2026 net loss more than doubled year over year to $20.34 million.
  • Research and development expenses more than doubled to $17.78 million due primarily to higher soquelitinib clinical trial and personnel costs.
  • Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, providing expected funding into the second quarter of 2028.
  • Enrollment remained on track in soquelitinib’s registrational Phase 3 peripheral T-cell lymphoma and Phase 2 atopic dermatitis trials.
  • Initial hidradenitis suppurativa trial data are expected in the first half of 2027; a Phase 2 asthma trial should begin by Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871641) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.